Infant Protection Against Respiratory Syncytial Virus (RSV) by Maternal RSV Vaccination or Receipt of Nirsevimab, and Intent for Nirsevimab Receipt, United States [Dataset]

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• Ask aRCie About This Resource

About

This dataset provides monthly estimates of infant protection against RSV that were calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM). The data included adult females aged 18-49 with infants under 8 months born since April 1, 2024. The survey relies on parent-reported receipt of nirsevimab to assess protection.

---

Tags

Focus Area: Infectious Disease

Audiences: Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Immunization; Infant; Pregnant Women; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Dataset; Antibodies, Monoclonal, Humanized; Surveys and Questionnaires

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Meeting Summary: State and Local Implementation Strategies for Increasing Access to Contraception During Zika Preparedness and Response — United States, September 2016 2017 · Centers for Disease Control and Prevention (CDC), Association of Schools & Programs of Public Health Fact Sheet: United States Response to the Clade I Mpox Outbreak in Several African Countries 2024 · Centers for Disease Control and Prevention (CDC) Clade I Monkeypox Outbreak Originating in Central Africa 2025 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---